Ping Yu

Ms. Ping Yu

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2025 in Land
Verified
Journal Article
Open access
PDF file
PYPing Yu
Ping Yu
Yu ZhangYu Zhang
Yu Zhang
Urban waterfront public space is a key infrastructure for enhancing citizens’ well-being. However, rapid urbanization squeezes out blue and green spaces in cities, and extreme weather challenges exist in winter cities, resulting in unmet needs and a significant decline in citizens’ satisfaction. There is an urgent need to optimize design to bridge the gap between supply and demand. This study proposes a workflow for optimizing the design of waterfront spaces in winter cities based on the KANO-IPA model from the perspective of users’ demands. We constructed a systematic and comprehensive set of spatial demand indicators for waterfront public space in winter cities, covering seven demand dimensions and 42 indicators. A satisfaction survey was conducted across 12 sample reaches in northeastern China. We used the KANO model to classify the attributes of spatial demand indicators, then applied IPA analysis to evaluate them, and finally calculated priority indices to quantify their priority sequences. Based on this, we proposed three-phase optimization strategies: near-term priority upgrading, medium-term steady promotion, and far-term charm enhancement, offering recommendations for improving waterfront public spaces in winter cities. This study provides long-term support for urban regeneration, resource management, and waterfront public space design in winter cities.

20 May 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
YSYuan-kai Shi
Yuan-kai Shi
XZXin Zhang
Xin Zhang
XLXiaoming Li
Xiaoming Li
JXJianping Xu
Jianping Xu
YHYong He
Yong He
LBLilian Bu
Lilian Bu
E21187 Background: Lung cancer is the leading cause of cancer related mortality worldwide. Approximately 85% of lung cancer is Non-Small Cell Lung Cancer (NSCLC). The clinical profiles and routine practice of advanced NSCLC in China have yet to be described. Methods: This is a multicenter, prospective non-interventional study enrolling and following adult patients who were newly diagnosed with unresectable Stage IIIB or IV NSCLC and received first-line systemic therapy between June, 2015 and October, 2017 in multiple regions in China, to describe the patient journey in terms of diagnosis, treatment, and clinical outcomes. Patient and disease characteristics were analyzed, treatment distribution and duration was evaluated. If in time, survival data will be presented. Results: Overall 1324 patients met the eligibility criteria and were included in the analysis. Median age was 60 years; 65.1% were male; 44.0% were non-smokers; 74.0% were adenocarcinoma, 21.5% were squamous cell carcinoma. The epidermal growth factor receptor (EGFR) mutation testing rate was 44.3% (587/1324). Among patients tested for EGFR, EGFR mutation (EGFRmut) rate was 48.7% (286/587) and among those mutations 87.4%(250/286) were del 19 or exon 21 mutations. Patients with EGFRmut NSCLC were more likely to be female, non-smoker, with stage IV non-squamous tumors. A total of 1101 (83.2%) patients received first line chemotherapy, and 402 (30.4%) patients received first line targeted therapy. Among 286 patients with EGFRmut NSCLC, majority (67.1%) patients received an EGFR tyrosine kinase inhibitor (TKI), with a longer median treatment duration (11.8 months) compared to those receiving chemotherapy (3.7 months) in the first line setting. Conclusions: Our data show that the characteristics of Chinese advanced NSCLC patients, including their EGFR testing and mutation rates, were generally consistent with previous reports. Majority EGFRmut advanced NSCLC patients received an EGFR TKI, and the duration of first line EGFR TKI was longer than that of chemotherapy for EGFRmut patients in this study. Clinical trial information: NCT02458651.